Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China flag China · Delayed Price · Currency is CNY
54.76
+0.34 (0.62%)
Apr 29, 2026, 3:00 PM CST
-15.69%
Market Cap 4.21B
Revenue (ttm) 898.20M
Net Income (ttm) 176.46M
Shares Out 77.38M
EPS (ttm) 2.21
PE Ratio 24.58
Forward PE n/a
Dividend 2.00 (3.68%)
Ex-Dividend Date n/a
Volume 320,463
Average Volume 413,638
Open 54.19
Previous Close 54.42
Day's Range 54.01 - 55.10
52-Week Range 54.01 - 78.20
Beta 0.44
RSI 26.47
Earnings Date Apr 20, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te... [Read more]

Sector Healthcare
Founded 2009
Employees 960
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688606
Full Company Profile

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.

Financial Statements

News

There is no news available yet.